My thoughts after the webinar:
Good news:
- We're finally headed back to "the clinic" and we'll be there soon (possibly starting this calendar year).
- Funding for the IIB is largely sorted. There will be no significant near-term dilution.
- We should have placebo-controlled results by early 2024.
Bad news:
- The funding we needed for the original IIB/III plan was not available under attractive terms. (reading between the lines on what MD said.)
- Potential partners told us to pound sand until we have placebo controlled results (reading between the lines on what CG said.)
Other thoughts:
- It sounds like our goal has changed from let's usher ATL1102 to commercialization for DMD and go it alone to let's partner it out/sell it after a successful Phase IIB (my interpretation).
- The PIP with EMA is still active if/when we start the approvable Phase III trial there.
- Forums
- ASX - By Stock
- PER
- Ann: ATL1102 Revised Plans accelerate reporting of unblinded data
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-53
-
-
- There are more pages in this discussion • 299 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
-0.001(1.23%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 8.0¢ | $63.52K | 777.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 97561 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 0.080 |
2 | 212658 | 0.078 |
1 | 200000 | 0.077 |
3 | 91500 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 97561 | 1 |
0.083 | 214000 | 1 |
0.084 | 67142 | 2 |
0.085 | 141000 | 2 |
0.086 | 106100 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |